AU2006227283B2 - Biomarkers for efficacy of aliskiren as a hypertensive agent - Google Patents

Biomarkers for efficacy of aliskiren as a hypertensive agent Download PDF

Info

Publication number
AU2006227283B2
AU2006227283B2 AU2006227283A AU2006227283A AU2006227283B2 AU 2006227283 B2 AU2006227283 B2 AU 2006227283B2 AU 2006227283 A AU2006227283 A AU 2006227283A AU 2006227283 A AU2006227283 A AU 2006227283A AU 2006227283 B2 AU2006227283 B2 AU 2006227283B2
Authority
AU
Australia
Prior art keywords
gene
snp
individual
aliskiren
agtr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006227283A
Other languages
English (en)
Other versions
AU2006227283A1 (en
Inventor
Jessie Gu
Joanne Meyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2006227283A1 publication Critical patent/AU2006227283A1/en
Application granted granted Critical
Publication of AU2006227283B2 publication Critical patent/AU2006227283B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2006227283A 2005-03-22 2006-03-20 Biomarkers for efficacy of aliskiren as a hypertensive agent Ceased AU2006227283B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US66424805P 2005-03-22 2005-03-22
US60/664,248 2005-03-22
US74240106P 2006-02-06 2006-02-06
US60/742,401 2006-02-06
PCT/US2006/009913 WO2006102177A2 (en) 2005-03-22 2006-03-20 Biomarkers for efficacy of aliskiren as a hypertensive agent

Publications (2)

Publication Number Publication Date
AU2006227283A1 AU2006227283A1 (en) 2006-09-28
AU2006227283B2 true AU2006227283B2 (en) 2010-07-01

Family

ID=37024459

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006227283A Ceased AU2006227283B2 (en) 2005-03-22 2006-03-20 Biomarkers for efficacy of aliskiren as a hypertensive agent

Country Status (8)

Country Link
US (1) US20100240760A1 (enExample)
JP (1) JP2008538549A (enExample)
KR (1) KR20080005926A (enExample)
AU (1) AU2006227283B2 (enExample)
BR (1) BRPI0609702A2 (enExample)
CA (1) CA2600525A1 (enExample)
MX (1) MX2007011697A (enExample)
WO (1) WO2006102177A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0609702A2 (pt) * 2005-03-22 2010-04-20 Novartis Ag biomarcadores para a eficácia de aliskiren como um agente hipertensivo
PT2205279E (pt) * 2007-09-28 2011-07-11 Novartis Ag Associação farmacêutica de aliscireno e valsartan
CN108660205A (zh) * 2018-07-04 2018-10-16 刘城 一种糖尿病遗传风险评估试剂盒及其运用
CN111024960B (zh) * 2019-12-27 2023-02-17 广州阳普医疗科技股份有限公司 用于高血压血样检测的添加剂、试剂盒和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988008457A1 (en) * 1987-04-30 1988-11-03 Biotechnology Research Partners, Ltd. Hypertension-related blood tests useful as genetic markers
WO2000022166A2 (en) * 1998-10-14 2000-04-20 Pyrosequencing Ab Genes for assessing cardiovascular status and compositions for use thereof
PL219032B1 (pl) * 2002-05-17 2015-03-31 Novartis Ag Kompozycja farmaceutyczna zawierająca alskiren, amlodypinę i hydrochlortiazyd, kombinacja zawierająca te składniki, zastosowanie wspomnianej kombinacji oraz zestaw handlowy zawierający wspomnianą kombinację
US8304190B2 (en) * 2005-02-02 2012-11-06 Royal College Of Surgeons In Ireland Pharmacogenomics of blood pressure lowering agents
BRPI0609702A2 (pt) * 2005-03-22 2010-04-20 Novartis Ag biomarcadores para a eficácia de aliskiren como um agente hipertensivo

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Arnett D. et al. Drug Development Research, 2004, vol. 62, pp. 191-199 *
Kurland L. et al. American Journal of Hypertension, 2004, vol. 17, no. 1, pp. 8-13 *

Also Published As

Publication number Publication date
BRPI0609702A2 (pt) 2010-04-20
WO2006102177A2 (en) 2006-09-28
US20100240760A1 (en) 2010-09-23
JP2008538549A (ja) 2008-10-30
MX2007011697A (es) 2007-11-16
WO2006102177A3 (en) 2007-05-10
KR20080005926A (ko) 2008-01-15
CA2600525A1 (en) 2006-09-28
AU2006227283A1 (en) 2006-09-28

Similar Documents

Publication Publication Date Title
US20100035251A1 (en) BioMarkers for the Progression of Alzheimer's Disease
US20100249107A1 (en) Biomarkers for Alzheimer's Disease Progression
US20070065821A1 (en) Methods for the prediction of suicidality during treatment
EP1869214A2 (en) Biomarkers for pharmacogenetic diagnosis of type 2 diabetes
AU2006227283B2 (en) Biomarkers for efficacy of aliskiren as a hypertensive agent
WO2006060429A2 (en) Identification of variants in histone deacetylase 1 (hdac1) to predict drug response
EP1835909A2 (en) Biomarkers for identifying efficacy of tegaserod in patients with chronic constipation
RU2408363C2 (ru) Биомаркеры для оценки эффективности алискирена в качестве гипертензивного агента
WO2006110478A2 (en) Mutations and polymorphisms of epidermal growth factor receptor
US20090281090A1 (en) Biomarkers for the prediction of responsiveness to clozapine treatment
WO2007109183A2 (en) Mutations and polymorphisms of fms-related tyrosine kinase 1
WO2007002217A2 (en) Mutations and polymorphisms of bcl-2
CN101146915A (zh) 高血压药阿利克仑功效的生物标志物
WO2007121017A2 (en) Mutations and polymorphisms of fms-like tyrosine kinase 4
WO2007058991A2 (en) Mutations and polymorphisms of c-abl

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired